Lazertinib + Amivantamab: A New Chemotherapy-Free Option for EGFR-Mutated Advanced NSCLC
/ Antonio Passaro / Jan Andreasen
Thoraxpatologien er en aktiv faktor i behandlingen af lungecancer
/ Eric Santoni Rugiu / Amanda Feldballe Bernholm
Eric Santoni-Rugiu: Vejen fra leverpatologi til nyudnævnt professor i thorakal patologi
/ Eric Santoni Rugiu / Jan Andreasen
New Treatment Possibilities Improve Future Outcomes of Lung Cancer
/ BestPractice Nordic
No Major Breakthroughs in Lung Cancer Compared to ESMO 2023
/ BestPractice Nordic
Highlights fra ESMO 2024 om lungecancer
/ Jens Benn Sørensen
Høydepunkter fra ESMO 2024 om lungekreft
/ Bjørn Henning Grønberg